Skip to main content

Search

Show all results for

Home

Person

Stephan Wullschleger

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2026 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (10)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor- reactive CD8+T cells and reprogramming macrophages

Douglas Hanahan, Krisztian Homicsko, Stephan Wullschleger, Mélanie Louise Tichet, Agnieszka Alicja Chryplewicz

Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most pa-tients respond transiently at best, highlighting the importance of understanding mechanisms underlying resistance. Herein, we evaluated the effects o ...

CELL PRESS2023

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells

Douglas Hanahan, Stephan Wullschleger, Petra Catalina Schwalie, Mélanie Louise Tichet, Maria Karagianni

Expansion and differentiation of antigen-experienced PD-1(+)TCF-1(+) stem-like CD8(+) T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade(1-4). Hashimoto et al. have shown that, in chronic infections, administr ...

NATURE PORTFOLIO2022

Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression

Douglas Hanahan, Krisztian Homicsko, Stephan Wullschleger, Mohammad Sadegh Saghafinia, Iacovos Michael, Giovanni Ciriello

Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet tumors (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP tumors has been obscure. Herein, using multi-omics ap ...

AMER ASSOC CANCER RESEARCH2021